Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30526295 | 1.00 | ALDH1A1 (0.45) | ALDH1A1LMNAKDM4ESTAT3HIF1A | |
| SCHEMBL14026572 | 0.81 | KDM4E (0.55) | ALDH1A1LMNAKDM4ESTAT3HIF1A | |
| SCHEMBL492273 | 0.79 | ALDH1A1 (0.56) | ALDH1A1LMNAKDM4ESTAT3HIF1A | |
| SCHEMBL30526306 | 0.79 | ALDH1A1 (0.40) | ALDH1A1LMNAKDM4ESTAT3HIF1A | |
| SCHEMBL25969374 | 0.79 | ALDH1A1 (0.40) | ALDH1A1LMNAKDM4ESTAT3HIF1A | |
| SCHEMBL8802172 | 0.76 | ADORA2A (0.37) | KDM4ESTAT3HIF1AADORA2AADORA1 | |
| SCHEMBL8801559 | 0.75 | ALDH1A1 (0.39) | ALDH1A1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL8801593 | 0.75 | KDM4E (0.41) | ALDH1A1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL25343179 | 0.75 | PTGER4 (0.40) | ALDH1A1LMNADYRK1A | |
| SCHEMBL30526303 | 0.75 | PTGER4 (0.40) | ALDH1A1LMNADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-8404856-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8273891-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120232062-A1 | AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION | EIGER BIOPHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232062-A1 | AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION | EIGER BIOPHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8106066-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-01-31 | — | — | US | disclosed |
| WO-2011049987-A2 | AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION | EIGER BIOPHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-7932248-B2 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ANTHONY NEVILLE J | 2010-11-11 | — | — | US | disclosed |
| US-20100256181-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| WO-2007056582-A1 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2007-04-05 | — | — | US | disclosed |
| WO-2007038367-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007024789-A1 | PYRROLOPYRIDINE, PYRROLOPYRIMIDINE AND PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON GENETICS INCORPORATED (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2006124897-A2 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITION | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| EP-0627432-B1 | 6-Piperazinyl-1H-pyrazolo [3,4-b]pyridine-3-carboxylic Acids, Esters, Amides and related compounds, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0627432-A1 | 6-Piperazinyl-1H-pyrazolo [3,4-b]pyridine-3-carboxylic Acids, Esters, Amides andrelated compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5300498-A | Treating depression, obsessive compulsive disorder | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232062-A1 | AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, AZI2, ZC3HAV1 | ALDH1A1 564/4885LMNA 4581/4885KDM4E 1163/4885 |
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RNGTT, RRM2B, RRM2 | ALDH1A1 2863/4885LMNA 3081/4885KDM4E 302/4885 |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A1 4633/4885LMNA 2277/4885KDM4E 3667/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | ALDH1A1 2944/4885LMNA 1093/4885KDM4E 1641/4885 |
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA2 | ALDH1A1 1707/4885LMNA 2847/4885KDM4E 3529/4885 |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | DPYD, TYMP, PNKP | ALDH1A1 1240/4885LMNA 3717/4885KDM4E 3660/4885 |
| US-20100256181-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLB, POLR2A, RRM2B | ALDH1A1 2088/4885LMNA 949/4885KDM4E 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.